Sorafenib, a multi-kinase (Raf, VEGFR2, and PDGFR-β) inhibitor with STAT3 inhibitory activity FDA approved for other solid malignancies, was shown to inhibit the proliferation of GBM in vitro, likely through its effects on AKT and MAPK [166,167]. This evidence concerns the gene KDR and glioblastoma.